OSAKA, Japan–(BUSINESS WIRE)–The U.S. FDA has accepted Santen’s NDA for intravitreal (IVT) sirolimus (440 µg) for the treatment of non-infectious uveitis of the posterior segment. The PDUFA action date is December 24, 2017.
Category: Business
Aerie Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 2, 2017
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), (the “Company”), announced today that its first quarter 2017 financial results will be released after the market closes on Tuesday, May 2, 2017. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company’s website at http://
US Market Report for Perimeters 2017: Sales are Relatively Immune to Economic Crises – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “US Market Report for Perimeters 2017 – MedCore” report to their offering. The slow but steady growth of the perimeter market is stimulated by the aging population and thei…
US Market Report for Autorefractors and Keratometers 2017: Driven by Increasing Popularity of Three-in-One Combination Devices – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “US Market Report for Autorefractors and Keratometers 2017 – MedCore” report to their offering. There were essentially no standalone autorefractor or keratometer devices le…
US Market Report for Optical Biometry 2017: Driven by Expansion of New & Existing Cataract Surgery Practices – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “US Market Report for Optical Biometry 2017 – MedCore” report to their offering. The optical biometry device market is expected to grow over the forecast period due to sust…
Global Ophthalmic Femtosecond Lasers Market 2017-2021 with Abbott Medical Optics, Alcon, Bausch & Lomb, Carl Zeiss Meditec & Ziemer Ophthalmic Systems Dominating – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Ophthalmic Femtosecond Lasers Market 2017-2021” report to their offering. The analysts forecast the global ophthalmic femtosecond lasers market to grow at a CAGR of…
Ocular Therapeutix™ to Present Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced new data to be presented from its most recent Phase 3 study evaluating the efficacy and safety of DEXTENZA™ (dexamethasone insert, 0.4mg) for intracanalicular use, for the treatment of ocular pain and inflammation following cataract surgery, at the upcom
US Market Report for Wavefront Aberrometers 2017 – Unit Sales, ASPs, Market Value & Growth Trends – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “US Market Report for Wavefront Aberrometers 2017 – MedCore” report to their offering. The wavefront aberrometer market is expected to grow over the forecast period. Wavefr…
United States Binocular Indirect Ophthalmoscopes Market Report 2017 – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “US Market Report for Binocular Indirect Ophthalmoscopes 2017 – MedCore” report to their offering. The market is expected to increase over the forecast period. With the ong…
Ophthalmic Instrumentation Market 2015-2022 – Global Strategic Business Report 2017 – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Ophthalmic Instrumentation – Global Strategic Business Report” report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived
Medical Fiber Optics market 2015-2022 – Global Strategic Business Report 2017 – Surgical Lights, Dental Lights, Endoscopes Lasers, Sensors & Others – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Medical Fiber Optics – Global Strategic Business Report” report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, …
Beaver-Visitec International to Acquire Malosa Medical
WALTHAM, Mass.–(BUSINESS WIRE)–Beaver-Visitec International, Inc. announced today that it has acquired Malosa Medical.
Glaukos Corporation to Release First Quarter 2017 Financial Results after Market Close on May 3
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release first quarter 2017 financial results after the market close on Wednesday, May 3, 2017. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 3,
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Lucentis® (ranibizumab injection) 0.3 mg for the monthly treatment of all forms of diabetic retinopathy. The most common cause of vision loss in people with diabetes, diabetic retinopathy is the leading cause of blindness among adults aged 20 to 741 and affects nearly 7.7 million people in the U.S.2 With this
Global Protective Eyewear Market to Reach $2.79 Billion by 2024 – By Design, Type & End User – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Protective Eyewear Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 to 2024…
Celebrate Ohio Bioscience at the Great Lakes Science Center
COLUMBUS, Ohio–(BUSINESS WIRE)–#Ohio–BioOhio is excited to host the 2017 BioOhio Annual Conference and 30th Anniversary Celebration later this month in Cleveland, the city where we were founded in 1987. An opening reception will be held April 23, wi…
Second Sight’s Argus II Retinal Prosthesis Implanted in First Patient in Asia
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to provide some useful vision to blind patients, today announced that the Argus® II Retinal Prosthesis System (“Argus II”) has been implanted in the first patient in Asia through an exclusive distribution partnership with Orient Europharma Co., Ltd. (OEP) and with charitable support from t
International Study Shows Two Glaukos iStent® Trabecular Micro-Bypass Stents and One Topical Medication Deliver Sustained IOP Reduction
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a study published in Clinical Ophthalmology showed that two iStent® Trabecular Micro-Bypass Stents and one topical ocular hypotensive medication achieved a 38% reduction in mean medicated intraocular pressure (IOP) three years
Retinaprothesensystem Argus II von Second Sight beim ersten Patienten in Asien implantiert
SYLMAR, Kalifornien–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) („Second Sight“ oder „das Unternehmen“), ein Entwickler, Hersteller und Vermarkter von implantierbaren Sehprothesen, die blinden Patienten ein gewisses, für sie nützliches Sehvermögen bringen sollen, gab heute bekannt, dass das Retinaprothesensystem Argus® II („Argus II“)beim ersten Patient in Asien implantiert wurde. Möglich gemacht wurde dies durch eine exklusive Vertriebspartnerschaft mit Orient Europharm
La protesi retinica Argus II di Second Sight impiantata nel primo paziente asiatico
SYLMAR, California–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (Nasdaq:EYES) (“Second Sight” o “la società”), un’azienda che sviluppa, fabbrica e commercializza protesi oftalmiche impiantabili che consentono di recuperare parzialmente il senso della vista a pazienti che lo hanno perso, oggi ha annunciato che il sistema di protesi retinica Argus® II (“Argus II”) è stato impiantato nel primo paziente asiatico attraverso un contratto di distribuzione esclusiva stipulato con Orient Europh